Skip to main content
Fig. 2 | EJNMMI Research

Fig. 2

From: A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Fig. 2

PBPK model prediction results per group (solid lines) for [68Ga]Ga-DOTATATE (A) and [68Ga]Ga-HA-DOTATATE (B), including minimum and maximum population ranges (dashed lines) that were based on administered peptide amount ranges, SSTR2 variability in organs, tumor blood flow variability and tumor blood volume variability. Missing data in group 2 for [68Ga]Ga-DOTATATE primary tumor uptake due to resection of the primary tumor for all patients (n = 4)

Back to article page